HC Wainwright & Co. Reiterates Buy on Amylyx Pharmaceuticals, Maintains $55 Price Target
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Ananda Ghosh reiterates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and maintains $55 price target.
HC Wainwright & Co. analyst Ananda Ghosh reiterates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and maintains $55 price target.
